Nonexpanded mesenchymal stem cells for regenerative medicine: yield in stromal vascular fraction from adipose tissues

The adipose-derived stromal vascular fraction (SVF) represents a rich source of mesenchymal cells, potentially able to differentiate into adipocytes, chondrocytes, osteoblasts, myocytes, cardiomyocytes, hepatocytes, and neuronal, epithelial, and endothelial cells. These cells are ideal candidates for use in regenerative medicine, tissue engineering, including gene therapy, and cell replacement cancer therapies. In this work, we aimed to the optimization of the adipose SVF-based therapy, and the effect of the collection site, surgical procedure, and tissue processing techniques on SVF yield was evaluated in terms of cell recovery and live cells, taking into account the effect of gender, age, and body mass index. Adipose tissue samples were recovered from 125 informed subjects (37 males and 88 females; mean age: 51.31 years; range: 15-87 years), and digested in different condition with collagenase. A multivariate linear model put in evidence that in males the best collection site in terms of yield is located in the abdomen, whereas in females the biopsy region do not influence cell recovery; the collection technique, the age, and the body mass index of donor seem not to influence the cell yield. The tissue-processing procedures strongly modify the yield and the vitality of cells: a collagenase concentration of 0.2% and a digestion time of 1h could be chosen as the best operating conditions

Sistemi microparticellari per la veicolazione di farmaci, cellule e molecole bioattive.

L’impiego di sistemi microparticellari per la veicolazione, il direzionamento e il rilascio controllato di farmaci è ormai consolidato nella terapia farmacologica di molte patologie; nel corso degli anni sono state messe a punto svariate tecnologie sia per la realizzazione di prototipi, sia per la produzione industriale di sistemi sofisticati. E’ stato possibile, pertanto, ottimizzare le potenzialità terapeutiche di farmaci di origine sintetica e biotecnologica. Recentemente tali sistemi sono stati proposti anche per la veicolazione di cellule nel campo delle Terapie Avanzate e nella medicina rigenerativa: le tecnologie farmaceutiche classiche sono state utilizzate per la realizzazione di forme farmaceutiche innovative iniettabili o impiantabili. In questo contesto, vengono descritti i più comuni sistemi microparticellari, ed in particolare microcapsule e microsfere, impiegati per la somministrazione transmucosale e parenterale di farmaci. Vengono trattate, inoltre, alcune problematiche relative alla veicolazione di cellule destinate all’impiego in protocolli clinici, mediante processi validabili e secondo le linee guida europee per la produzione di medicinali per le Terapie Avanzate

Enzyme controlled release of celecoxib from inulin based nanomicelles

Celecoxib (CLX) delivery and its enzyme-sensitive release from Inulin-d-alfa-tocopherol succinate (INVITE) nanomi- celles are the main goals of this paper. CLX is a highly hydrophobic drug belonging to BCS class II (low solubility, high permeability). For this reason its formulation is problematic and its biopharmaceutical performances strongly depend from the applied delivery system. In the last years, INVITE nanomicelles has been shown their potential in the delivery of highly hydrophobic drugs such as curcumin and for this reason have been chosen as a good candidate for CLX delivery. Furthermore, due to the presence of ester bonds between INU and VITE it has been supposed that the drug release could show enzyme-sensitive (esterase) behaviors. Thus CLX was loaded in INVITE nanomicelles, the loading was quantified and the physical stability was evaluated up to 90 days, finally, drug release studies in the presence or in the absence of the specific enzyme esterase were performed